Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2491-2500 Newer>

The Motley Fool November 7, 2005 Stephen D. Simpson	All's Not Lost at Guidant Eroding sales, a partner with cold feet, and all sorts of litigation and investigation cloud Guidant's skies. Investors, take note.
The Motley Fool November 4, 2005 Rich Duprey	Merck Eases Its Pain The pharmaceutical giant wins an important Vioxx trial. And while it's a welcome reprieve for the company, the decision doesn't seem to warrant the enthusiasm with which the market greeted the decision.
The Motley Fool November 3, 2005 Stephen D. Simpson	Becton, Dickinson: More Boring Growth This company may seem to be just a collection of boring businesses making things like syringes, reagents, and safety products. But shareholders aren't feeling too bored with today's strong stock performance.
The Motley Fool November 3, 2005 Stephen D. Simpson	The At-Odds Couple Johnson & Johnson seems to want out, but Guidant looks willing to grab the shotgun to see that this union is completed. Investors, should the deal fall through, look for J&J to continue shopping and don't be surprised if Guidant attracts attention from Abbott Labs or Boston Scientific.
The Motley Fool November 2, 2005 Stephen D. Simpson	No Colic at Pediatrix Despite hurricanes and a higher percentage of Medicaid patients, the newborn-care health products maker still had a solid quarter. Investors should note, though, that there are reimbursement and litigation risks here. As such, a little extra due diligence is a good idea.
The Motley Fool November 2, 2005 Stephen D. Simpson	AMO Focuses on the Giants Advanced Medical Optics sets its sights on the big players in eye care. Will David be able to take on the Goliaths? Investors, take note.
The Motley Fool November 2, 2005 Brian Gorman	Medco's Bitter Pill The pharma benefits manager has hit a speed bump but looks well-positioned for the long haul. Investors, take note.
The Motley Fool November 2, 2005 Rich Duprey	Can Candela Regain Focus? Aesthetic laser maker reports strong gains, but can it do so consistently? It has new products, new distributors, and new markets to expand into, along with a shareholder-friendly stock buyback program.
The Motley Fool November 1, 2005 Rich Duprey	Eisai's Good Medicine The Japanese pharmaceutical reports record sales and earnings on the strength of its Alzheimer's treatment. Sales and profit growth have caused Eisai's share price to surge by about 33% since the beginning of the year.
The Motley Fool November 1, 2005 Brian Gorman	Kendle's Resurgence Can the contract pharmaceutical researcher continue its growth without more acquisitions? Despite the vibrant growth and its operational progress, Kendle still is at a disadvantage to larger rivals like Charles River Laboratories and PPD.
<Older 2491-2500 Newer> Return to current articles.